Literature DB >> 23234804

Assessment of the performance of algorithms for cervical cancer screening: evidence from the Ludwig-McGill cohort study.

M Chevarie-Davis1, A V Ramanakumar, A Ferenczy, L L Villa, E L Franco.   

Abstract

OBJECTIVE: There are currently multiple tests available for cervical cancer screening and the existing screening policies vary from country to country. No single approach will satisfy the specific needs and variations in risk aversion of all populations, and screening algorithms should be tailored to specific groups. We performed long term risk stratification based on screening test results and compared the accuracy of different tests and their combinations.
METHODS: A longitudinal cohort study of the natural history of HPV infection and cervical neoplasia enrolled 2462 women from a low-income population in Brazil. The interviews and cervical screening with cytology and HPV DNA testing were repeated according to a pre-established protocol and the subjects were referred for colposcopy and biopsy whenever high grade lesions were suspected. We compared the specificity, sensitivity and predictive values of each screening modality. Long term risk stratification was performed through time-to-event analyses using Kaplan-Meier analysis and Cox regression.
RESULTS: The best optimization of sensitivity and specificity was achieved when using dual testing with cytology and HPV DNA testing, whereby the screening test is considered positive if either component yields an abnormal result. However, when allowing 12months for the detection of lesions, cytology alone performed nearly as well. Risk stratification revealed that HPV DNA testing was not beneficial for HSIL cases, whereas it was for ASCUS and, in some combinations, for negative and LSIL cytology.
CONCLUSION: Our results suggest that some high risk populations may benefit equally from cytology or HPV DNA testing, and may require shorter intervals between repeat testing.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23234804      PMCID: PMC4405789          DOI: 10.1016/j.ygyno.2012.12.008

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  16 in total

1.  Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study.

Authors:  M H Stoler; M Schiffman
Journal:  JAMA       Date:  2001-03-21       Impact factor: 56.272

2.  Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia.

Authors:  N F Schlecht; S Kulaga; J Robitaille; S Ferreira; M Santos; R A Miyamura; E Duarte-Franco; T E Rohan; A Ferenczy; L L Villa; E L Franco
Journal:  JAMA       Date:  2001-12-26       Impact factor: 56.272

3.  Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil. Ludwig-McGill Study Group.

Authors:  E Franco; L Villa; T Rohan; A Ferenczy; M Petzl-Erler; G Matlashewski
Journal:  Rev Panam Salud Publica       Date:  1999-10

4.  Biopsy correlates of abnormal cervical cytology classified using the Bethesda system.

Authors:  L S Massad; Y C Collins; P M Meyer
Journal:  Gynecol Oncol       Date:  2001-09       Impact factor: 5.482

Review 5.  Chapter 7: Achievements and limitations of cervical cytology screening.

Authors:  Henry C Kitchener; Philip E Castle; J Thomas Cox
Journal:  Vaccine       Date:  2006-08-31       Impact factor: 3.641

6.  Overview of the European and North American studies on HPV testing in primary cervical cancer screening.

Authors:  Jack Cuzick; Christine Clavel; Karl-Ulrich Petry; Chris J L M Meijer; Heike Hoyer; Samuel Ratnam; Anne Szarewski; Philippe Birembaut; Shalini Kulasingam; Peter Sasieni; Thomas Iftner
Journal:  Int J Cancer       Date:  2006-09-01       Impact factor: 7.396

7.  Cumulative 5-year diagnoses of CIN2, CIN3 or cervical cancer after concurrent high-risk HPV and cytology testing in a primary screening setting.

Authors:  Heike Hoyer; Cornelia Scheungraber; Rosemarie Kuehne-Heid; Karin Teller; Christiane Greinke; Sabine Leistritz; Beate Ludwig; Matthias Dürst; Achim Schneider
Journal:  Int J Cancer       Date:  2005-08-10       Impact factor: 7.396

8.  Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.

Authors:  Marie-Hélène Mayrand; Eliane Duarte-Franco; Isabel Rodrigues; Stephen D Walter; James Hanley; Alex Ferenczy; Sam Ratnam; François Coutlée; Eduardo L Franco
Journal:  N Engl J Med       Date:  2007-10-18       Impact factor: 91.245

9.  Natural history of cervical squamous intraepithelial lesions: a meta-analysis.

Authors:  J Melnikow; J Nuovo; A R Willan; B K Chan; L P Howell
Journal:  Obstet Gynecol       Date:  1998-10       Impact factor: 7.661

Review 10.  2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests.

Authors:  Thomas C Wright; L Stewart Massad; Charles J Dunton; Mark Spitzer; Edward J Wilkinson; Diane Solomon
Journal:  Am J Obstet Gynecol       Date:  2007-10       Impact factor: 8.661

View more
  1 in total

1.  Assessing 10-Year Safety of a Single Negative HPV Test for Cervical Cancer Screening: Evidence from FOCAL-DECADE Cohort.

Authors:  Anna Gottschlich; Dirk van Niekerk; Laurie W Smith; Lovedeep Gondara; Joy Melnikow; Darrel A Cook; Marette Lee; Gavin Stuart; Ruth E Martin; Stuart Peacock; Eduardo L Franco; Andrew Coldman; Mel Krajden; Gina Ogilvie
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-10-20       Impact factor: 4.254

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.